Position
Fidelity in Arbutus Biopharma Corp
Back to the book · All holders of ABUS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $43.5K$4.50 → $4.80
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 136.6K | $656.8K | — | — | — | 0.0% |
| Q1 2026 | 145.1K | $653.1K | $4.50 | −$42.3K | $38.6K | 0.0% |
| Q2 2026 | 267.2K | $1.28M | $4.80 | $43.5K | $585.9K | 0.0% |